How regenerative medicine M&A performed in the pharmaceutical industry in Q2 2023

In value terms, regenerative medicine-related deal activity remained flat in Q2 2023 compared with the previous quarter and as compared to Q2 2022. Related deal volume increased by 300% in Q2 2023 versus the previous quarter and was 100% higher than in Q2 2022.

The top-ranked financial advisors supporting these M&A deals in Q2 2023 were Evercore; Guggenheim Partners; Houlihan Lokey with 1, 1, 1 deals respectively.

The top-ranked legal advisors supporting these M&A deals in Q2 2023 were Goodwin Procter; Cooley; Gibson, Dunn & Crutcher with 2, 1, 1 deals respectively.

For further understanding of GlobalData’s Regenerative Medicine in Medical – Thematic Research, buy the report here.

This content was updated on 18 July 2023

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Acquisition, Asset transactions and Mergers.

Urgent need for action as vaping spreads through social media

A University of Queensland research project will investigate the online influences behind young people taking up vaping, and develop social media content to support them

December 15, 2023

PMV to cut 30% of its workforce; Edgewise, Esperion announce public offerings

PMV Pharmaceuticals to cut 30% of its employees: The Princeton, NJ-based company had 62 full-time employees as of Feb. 28. It expects the cuts to extend

January 20, 2024

Bayer’s projects with Twist, Evotec; AbbVie buys out Parkinson’s drugmaker; A new drug discovery nonprofit in Toronto

Bayer teams up with Twist: The German drugmaker entered into a drug discovery deal with California biotech Twist Bioscience. Twist will use its synthetic antibody

October 6, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.